Centanafadine is the newest prescription option for attention-deficit/hyperactivity disorder (ADHD), and it works differently from almost every medicine that came before it. Approved by the U.S. FDA in July 2026 under the centanafadine brand name Simtriyo, it is a once-daily capsule for adults and children aged 6 and older.
Unlike classic stimulants, it blocks the reuptake of three brain chemicals at once: norepinephrine, dopamine and serotonin. That makes it the first triple reuptake inhibitor approved for centanafadine ADHD treatment. In this guide, you will learn how centanafadine works, what four Phase 3 trials showed, and what the centanafadine FDA approval means for patients and parents.
We also cover side effects, boxed warnings, how it compares with stimulants such as Adderall and Vyvanse, and what is known about centanafadine cost and launch timing. Whether you are a patient, a parent or a clinician, this article gives you plain-language answers. Every claim is tied to official or peer-reviewed sources, and anything still unconfirmed is clearly marked.
What Is Centanafadine?
Centanafadine is a prescription medicine for ADHD. It is taken by mouth as a once-daily extended-release capsule. The U.S. Food and Drug Administration (FDA) approved it in July 2026 for adults and for children aged 6 and older who weigh at least 20 kg (about 44 pounds), according to Otsuka’s announcement.
The drug did not start at Otsuka. It came to the company through its 2017 purchase of Neurovance, a deal that included $100 million upfront and up to $150 million in milestone payments, as Fierce Pharma reported. It then spent years in clinical trials before reaching the market.
Why does it matter? ADHD is common. The CDC counts about 7 million U.S. children and 15.5 million U.S. adults with the condition. Many of them stop or switch medicines because of side effects or poor results. A new option with a new mechanism gives doctors one more tool.
Centanafadine Brand Name: Simtriyo
People often search for the centanafadine brand name. It is Simtriyo. Otsuka makes it. The generic (chemical) name is centanafadine, and the brand name is what you will see on a prescription label.
Simtriyo comes in three capsule strengths: 140 mg, 210 mg and 280 mg, according to Drugs.com. Which strength a person gets depends on age and body weight:
- Children 6 to 12 years: 140 mg for 20 to under 35 kg, 210 mg for 35 to 50 kg, and 280 mg for over 50 kg.
- Teens 13 to 17 years: 280 mg once daily.
- Adults: a starting dose of 210 mg once daily, with a maximum of 280 mg.
These figures are for information only. Your prescriber sets the real dose, and the official label always wins.
Where Centanafadine Fits Among ADHD Drugs
Most ADHD medicines fall into two groups. Stimulants, such as methylphenidate and amphetamine, have been used for decades. Non-stimulants, such as atomoxetine (Strattera) and viloxazine (Qelbree), came later and are usually used when stimulants do not work or are not tolerated.
The FDA labels centanafadine a CNS stimulant, yet it is chemically and mechanically distinct from both older groups. Otsuka calls it a first-in-class drug. We explain why in the next section.
Triple Reuptake Inhibitor: How Centanafadine Works
Your brain cells talk to each other using chemical messengers called neurotransmitters. After one cell releases a messenger, the signal ends when the messenger is pulled back into the cell. That pull-back step is called reuptake.
A reuptake inhibitor blocks that step. The messenger stays in the gap between cells longer, so the signal lasts longer. Centanafadine does this for three messengers at the same time. That is why scientists call it a triple reuptake inhibitor. The label term is norepinephrine, dopamine, serotonin reuptake inhibitor, or NDSRI.
The Three Messengers in Plain Language
- Norepinephrine helps with alertness, focus and staying on task.
- Dopamine supports motivation, reward and planning. Low dopamine signaling is a long-standing theory behind ADHD.
- Serotonin is linked with mood, impulse control and emotional balance. This is the part that sets centanafadine apart.
Most older ADHD drugs act mainly on the first two. Adding serotonin may help with mood and emotional regulation, which many people with ADHD struggle with. That idea is still a hypothesis. The label itself says the exact way centanafadine helps ADHD is “not fully understood,” as Drugs.com notes.
Why a Triple Action May Matter
ADHD rarely travels alone. Anxiety, low mood and irritability are common companions. A drug that touches all three systems could, in theory, help more than one symptom group. Otsuka also reported a Phase 3b study in adults with both ADHD and anxiety. In that study, treatment beat placebo on the main ADHD scale.
Still, a theory is not proof. Centanafadine is approved only for ADHD. It is not approved for anxiety or depression. Anyone with those conditions should work with a clinician rather than self-treat.
Two Practical Notes on How It Behaves in the Body
The full pharmacology picture is still limited. Two details stand out in the label summary on Drugs.com:
- Centanafadine is a moderate CYP1A2 inhibitor. In one study it roughly doubled caffeine exposure. Heavy coffee or energy-drink use may feel stronger while on it.
- Alcohol can make the extended-release capsule release the drug too quickly. Avoid alcohol while taking it unless your doctor says otherwise.
Centanafadine for ADHD: What the Clinical Trials Showed
The case for centanafadine ADHD treatment rests on four randomized, double-blind, placebo-controlled Phase 3 trials. Two studied adults. Two studied children and teens. A fifth study, called Phase 3b, looked at adults who also had anxiety. All results below come from the manufacturer’s approval announcement and the clinician summary in ADDitude.
Adult Trials
The two adult pivotal studies (NCT03605680 and NCT03605836) ran for six weeks. Adults took a low or high dose of centanafadine, or placebo. Symptoms were scored with the Adult ADHD Investigator Symptom Rating Scale (AISRS).
Both dose groups improved more than placebo. Gains showed up as early as week one and held through week six. In ADDitude’s summary, about one in four adults on the drug had an improvement of 18 points or more, against 15.4% on placebo.
That gap is real but modest. It tells us the drug works for some adults, not for everyone.
Trials in Children and Teens
The two pediatric studies (NCT05428033 and NCT05257265) used the ADHD Rating Scale-5 (ADHD-RS-5). Only the high dose beat placebo in a statistically significant way. The low dose did not.
- Teens (13 to 17): about half of those on the high dose reached an improvement of 18 points or more, versus 23% on placebo.
- Children (6 to 12): about one in three on the high dose reached that mark, versus 23% on placebo.
For both groups, symptoms improved as early as week one. Early benefit matters to families, because waiting weeks for a medicine to work is hard on a child and on the whole household.
How Big Is the Effect?
Researchers often describe a drug’s strength with an “effect size.” Across the positive trials, the placebo-adjusted effect size for centanafadine fell between 0.24 and 0.40, according to a clinician’s review of the trial data. For context, the same review lists about 0.79 for the amphetamine class in adults, 0.49 for methylphenidate and 0.45 for atomoxetine.
Two cautions apply. First, these numbers come from different trials with different patients and scales, so they are only rough guides. Second, the figures are placebo-adjusted averages. Individual responses vary a lot in ADHD, and a person who does poorly on one drug may do well on another.
ADHD With Anxiety: The Phase 3b Study
About one month before approval, Otsuka reported topline results from a Phase 3b study. It enrolled adults with ADHD and co-existing anxiety. Treatment beat placebo on the AISRS. ADDitude reports the study had 315 adults, ran eight weeks and used 280 mg once daily, with anxiety scores also improving. Full data were still to be presented at a medical meeting when we reviewed the sources.
This result is encouraging, but it does not add an anxiety indication. The approved use remains ADHD only.
Long-Term Data and Gaps
A 52-week extension study followed adults who kept taking the drug, and early safety reports were broadly favorable. Even so, long-term effects on appetite, weight and growth in children are still being studied. The label tells doctors to monitor height and body mass index in young patients.
Also note a technical detail. Some trial doses and forms differ from the final approved capsule. For example, adult trials used a sustained-release product at different doses. Always use the current prescribing information, not trial doses, to understand real-world dosing.
Key Takeaway on Efficacy
The trials support centanafadine as an effective ADHD medicine across age groups, with early onset and a gentler side-effect profile than many stimulants. The effect looks smaller than the strongest stimulants in indirect comparisons. That makes it a practical option for people who need another path, not a clear replacement for every existing drug.
Centanafadine FDA Approval: Timeline and Status
The centanafadine FDA approval is the headline event of 2026 in ADHD care. The FDA approved the drug on July 24, 2026, according to Drugs.com, and Psychiatric Times covered the decision for children, adolescents and adults. Otsuka’s own press release followed in late July. You can check the agency’s current drug approvals on the FDA drugs page.
The approval came quickly after the application. The FDA accepted it for priority review, a faster track reserved for drugs that may offer a meaningful advantage.
Centanafadine Approval Timeline
| When | Milestone |
|---|---|
| 2017 | Otsuka acquires Neurovance, the developer of centanafadine |
| 2018 to 2025 | Four Phase 3 trials in adults, children and adolescents |
| November 2025 | Otsuka submits the New Drug Application (NDA) |
| January 2026 | FDA accepts the NDA for priority review |
| Mid-2026 | Phase 3b results in adults with ADHD and anxiety reported |
| July 24, 2026 | FDA approves Simtriyo (centanafadine) for ADHD in patients 6 and older |
| Later in 2026 | Launch expected after DEA scheduling |
The NDA and priority-review steps were reported by Psychiatric Times and HCPLive.
What Exactly Did the FDA Approve?
The approved use is the treatment of ADHD in adults and in children aged 6 and older who weigh at least 20 kg. It is not recommended for children under 6 or under 20 kg. The reasons given were a higher rate of weight loss and a lack of data in those groups.
The drug is not approved for anxiety, depression, binge eating or any other condition. Doctors can sometimes prescribe a drug “off label,” but that is a clinical judgment, not an endorsement from the FDA.
Why DEA Scheduling Comes Next
Here is the step many readers miss. The FDA classes centanafadine as a CNS stimulant, so it must go through a review by the U.S. Drug Enforcement Administration (DEA). The DEA decides whether it becomes a controlled substance and in which schedule. That review typically takes up to three months, as Fierce Pharma explained.
The schedule matters a great deal. Adderall and Vyvanse are Schedule II, the strictest category for medicines with accepted uses. That status limits refills and often adds paperwork. Analysts quoted by Fierce said a Schedule II rating could slow uptake, while a lower schedule could be a selling point. Trials showed low abuse potential, but the label still carries a boxed warning on abuse and misuse.
When we reviewed the sources, no final schedule had been published, and the drug was described as “expected later in 2026.” Because things move fast after approval, check Otsuka’s site or your pharmacist for the latest launch status.
Is Centanafadine Available Yet?
In the coverage we reviewed, the answer was “not yet.” Launch depends on DEA scheduling. Once the drug reaches pharmacies, supply will come from one maker, because it is a brand-only product with no generic.
Rising Public Interest
Public interest has jumped. Search interest in centanafadine is up about 537% in recent tracking, with roughly 12,000 searches in the “rising” tool. Much of that comes from parents and adults asking whether the new drug is right for them, and what it will cost.
Centanafadine Side Effects and Safety
Every ADHD drug has trade-offs, and centanafadine is no exception. This section covers common side effects, the two boxed warnings and the groups who should avoid it. It is a summary. Read the full prescribing information and talk to your doctor for your own risk.
Common Side Effects by Age
The label lists the most common reactions as those that occurred in at least 5% of patients and more often than with placebo. Here is how they break down, according to Otsuka’s announcement:
| Age group | Most common side effects |
|---|---|
| Children 6 to 12 | Rash, decreased appetite |
| Teens 13 to 17 | Decreased appetite, nausea, rash, headache, abdominal pain |
| Adults | Headache, decreased appetite, insomnia, nausea, dry mouth, diarrhea |
Most effects were mild. Understood reports that about one-third of adults and children, and half of teens, had side effects, compared with about a quarter of those on placebo. You can read that summary on Understood.
Boxed Warnings
A boxed warning is the FDA’s strongest alert. Centanafadine has two.
- Suicidal thoughts and behaviors in children and teens. In the six-week study, children aged 6 to 12 on the drug had higher rates than those on placebo. Parents should watch mood and behavior closely, especially early in treatment and after any dose change. Call the doctor right away about new or worsening mood changes.
- Abuse, misuse and addiction. Misuse can lead to overdose and death, especially at larger doses or by unapproved routes. Store the medicine securely and never share it.
Other Warnings and Precautions
The label also flags several risks that doctors need to watch:
- Blood pressure and heart rate. Both can rise. Doctors should check them after dose increases and from time to time.
- Heart disease. Avoid use in people with serious heart problems, such as cardiomyopathy, serious arrhythmia or coronary artery disease.
- Psychiatric reactions. New psychotic or manic symptoms may call for stopping the drug.
- Serious allergic reactions. These include anaphylaxis and angioedema.
- Growth in children. Doctors should track height, weight and linear growth.
- Circulation problems. The label notes peripheral vasculopathy, including Raynaud’s phenomenon.
- Serotonin syndrome. This is a risk with other serotonin-raising drugs, including many antidepressants.
- Tics. The drug can cause motor and verbal tics or worsen Tourette’s syndrome.
Who Should Not Take Centanafadine
The drug is contraindicated, meaning it should not be used, in these cases:
- Known allergy to centanafadine or any ingredient in the capsule
- Current use of a monoamine oxidase inhibitor (MAOI), or use within the last 14 days
- Current or past pheochromocytoma, a rare adrenal tumor
It is also not recommended for children under 6 or under 20 kg, or for people with severe liver problems. Drugs.com lists these points in its label summary.
A Note on Weight Loss and Appetite
Decreased appetite is one of the most common effects. The label says that in very young or very small children, the rate of weight loss was higher, which is one reason the drug is not recommended below 6 years or 20 kg. Parents of growing children should expect regular height and weight checks.
Reading the Safety Data Fairly
Indirect comparisons suggest the drug may cause less appetite loss and insomnia than some stimulants. That is helpful, but a reviewer points out that this may partly reflect how different trials record side effects, and the comparisons were funded by the sponsor. In plain terms, the safety story looks good, yet it is not proven superior. Real-world use over several years will tell us more.
Centanafadine vs Stimulants: How Do They Compare?
The question most readers ask is simple. Is centanafadine better than Adderall, Ritalin or Vyvanse? The honest answer is that nobody knows for sure yet. No head-to-head trial exists. Every registration trial compared the drug only with placebo. What we have are indirect comparisons, which are useful but imperfect.
Side-by-Side Comparison
| Feature | Centanafadine (Simtriyo) | Amphetamine drugs (Adderall, Vyvanse) | Methylphenidate (Ritalin) |
|---|---|---|---|
| Main action | Blocks reuptake of norepinephrine, dopamine and serotonin | Raises dopamine and norepinephrine | Blocks reuptake of dopamine and norepinephrine |
| Dosing | Once-daily extended-release capsule | Once daily (extended-release forms) | Short- and long-acting forms |
| Trial effect size (placebo-adjusted) | About 0.24 to 0.40 | About 0.79 (class estimate, adults) | About 0.49 (adults) |
| Time to first benefit | As early as week 1 | Often within hours to days | Often within hours to days |
| DEA status | Pending at last report | Schedule II | Schedule II |
| Brand or generic | Brand only | Generics available | Generics available |
Effect sizes come from a clinician’s review of published trials. They come from different studies, so treat them as rough.
Where Stimulants Still Lead
Stimulants have a long record and strong effects. An indirect analysis cited in that review found a statistically significant advantage for lisdexamfetamine (Vyvanse) over centanafadine of about 6.6 points on the adult AISRS scale. Understood, summarizing a similar analysis, says the new drug seems to work about as well as Ritalin and less well than Vyvanse. See Understood for that summary.
Stimulants also have generics, which keep prices lower. Supply of some stimulants has been tight in recent years, but many insurers cover them without fuss.
Where Centanafadine May Have an Edge
The same indirect analyses point to better tolerability. Compared with lisdexamfetamine, the review reports about 23 percentage points less appetite loss, 15 points less insomnia and 19 points less dry mouth. Against long-acting methylphenidate, insomnia was also lower.
The review adds a warning that is worth repeating. All 28 adverse-event comparisons favored the new drug. That unusual result may reflect how trials recorded events, not only the chemistry. The comparisons were also sponsor-funded.
A possible edge in scheduling is the other open question. If the DEA places centanafadine below Schedule II, prescribing could be easier. That is a prediction, not a decision.
Centanafadine vs Non-Stimulants
Non-stimulants such as Strattera (atomoxetine) and Qelbree (viloxazine) are not controlled substances. They can take weeks to build up. Understood notes that centanafadine may be easier to tolerate than Strattera, which often causes appetite loss or insomnia, and that its benefit appears within about a week. That is slower than many stimulants but faster than Strattera.
Analysts expect the drug to grow the non-stimulant segment of the market, according to Fierce Pharma, not simply take patients from one rival.
Who Might Consider the Switch?
A doctor may consider centanafadine when:
- Stimulants cause intolerable appetite loss, insomnia or dry mouth
- Stimulants did not work well enough
- A patient also has anxiety, and the doctor wants a medicine with a serotonin effect (though this is not an approved use)
- There are concerns about misuse and the family wants a lower-risk profile, pending the DEA decision
A doctor may avoid it in people with serious heart disease, those on an MAOI, and in anyone with a history of suicidal thoughts who cannot be closely watched.
Never Switch on Your Own
Do not stop a stimulant and start a new drug without medical advice. Stopping suddenly can bring back symptoms or cause a crash. Changing medicines also needs a plan for doses and overlap, which only your prescriber can set.
Centanafadine Cost, Insurance and Availability
The centanafadine cost is the second most common question after safety. Here is the plain answer: no U.S. price has been announced in any source we reviewed. Otsuka’s release did not disclose one, and neither Fierce Pharma, Understood nor Drugs.com lists one. We will not guess a number, because an invented price would mislead readers.
What We Do Know About Pricing
Several facts help set expectations, even without a sticker price:
- It is brand only. Simtriyo is a new patented drug, so there is no generic. Brand drugs usually cost more than generic Adderall or methylphenidate.
- Otsuka has big sales hopes. The company has set a peak-sales target above 100 billion yen, about $610 million, per Fierce Pharma. BioSpace put the opportunity at about $615 million. Those goals suggest a price set to compete with other brand ADHD drugs, but that is inference, not fact.
- Insurance may lag. Understood says it may not be covered by insurance right away. New drugs often need prior authorization, which means the insurer asks the doctor to explain why a cheaper drug will not do.
- Supply comes from one maker. Availability will depend on Otsuka’s manufacturing and distribution.
Centanafadine Cost vs Generic Stimulants
Generic amphetamine salts and generic methylphenidate are widely available and much cheaper for most people. Insurers often put them first. A step-therapy rule may require you to try a generic stimulant before they will pay for centanafadine. If you have already tried stimulants and had problems, your doctor can document that.
How to Prepare for the Cost Conversation
- Ask your insurer whether Simtriyo is on the formulary and whether prior authorization or step therapy applies.
- Ask your pharmacist when the drug will arrive. The DEA review must finish first.
- Ask Otsuka or your doctor’s office about savings or patient-assistance programs. We found no confirmed program in the sources we reviewed, so verify before you count on one.
- Compare monthly out-of-pocket costs for each option, including generics, once a price is public.
- Keep records of past drugs tried and why they failed. Insurers often ask for them.
When Will Pricing Be Public?
Pricing usually appears at or near launch. Because launch awaits DEA scheduling, expect price news in the same window. Check the FDA drugs page for regulatory updates and your pharmacist for real prices. We will not treat any figure as real until Otsuka or a pharmacy publishes it.
